Johnson & Johnson, which has lost hundreds of millions of dollars in jury awards over its Ethicon pelvic mesh products, scored its third defense verdict in 2022.

The July 1 verdict from a federal jury in Denver follows two other defense verdicts in March, one in Arizona and the other in West Virginia. This year’s victories contrast with Ethicon pelvic mesh trials that occurred prior to the COVID-19 pandemic, when juries awarded between $2.1 million to $120 million to plaintiffs.